REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

Trial Profile

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Anacetrapib (Primary)
  • Indications Cardiovascular disorders; Coronary disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL
  • Most Recent Events

    • 15 Nov 2017 More detailed results on the effects of anacetrapib on first and subsequent occlusive vascular events will be presented at American Heart Association Congress.
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 29 Aug 2017 According to Merck & Co media release, this trial was conducted in collaboration with the TIMI Study Group based at Brigham and Womens Hospital in Boston.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top